Further data from the phase 2 trial of show a significant reduction in enhancing MRI lesions with one of the doses tested but increases in liver enzymes may be an issue.
Read more
Latest Data on Evobrutinib, New MS Therapy Targeting B Cells
Posted in biotech/medical